Understanding MP.PA.147

Jul. 2025Important Notices

Understanding changes to the Diagnostic and Surveillance Colonoscopy, 18 Years Old and Older – MP.PA.147 policy

Effective date July 1, 2025 , the Diagnostic and Surveillance Colonoscopy, 18 Years Old and Older – MP.PA.147 policy contains clarifications in key areas:

Prior authorizations. As of July 1, 2025 MP.PA.147 now requires prior authorization for many codes across all lines of business. It is important to note that this policy applies only to diagnostic and surveillance colonoscopies, as screening exams are outside the scope of MP.PA.147.

Billing. MP.PA.147’s coding section clarifies how providers must bill the codes to denote a screening exam. The provider is responsible for clinical decisions and billing. For information on using modifier 33 and modifier PT for screening colonoscopies, please review the Colorectal Cancer Screening Billing Guide.

Learn more about MP.PA.147

Review the complete MP.PA.147 bulletin

Read the article in the July Provider Partner Update


Recent Announcements

CME Webinar: The State of Telehealth in 2026

Please join us for a live, CME-accredited webinar on Tuesday, Jan. 27, from noon to 1 p.m. that will share updates on the state of telehealth for 2026.
Dec. 2025Education/Webinars

Formulary updates effective Jan. 1, 2026

Review upcoming policy and operational updates
Dec. 2025Pharmacy Updates

Voluntary nationwide recall: Famotidine (Fresenius – November)

Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.
Nov. 2025Pharmacy Updates